GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (WBO:EVT) » Definitions » Cyclically Adjusted PB Ratio

Evotec SE (WBO:EVT) Cyclically Adjusted PB Ratio : 2.44 (As of Apr. 29, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Evotec SE Cyclically Adjusted PB Ratio?

As of today (2024-04-29), Evotec SE's current share price is €9.295. Evotec SE's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €3.81. Evotec SE's Cyclically Adjusted PB Ratio for today is 2.44.

The historical rank and industry rank for Evotec SE's Cyclically Adjusted PB Ratio or its related term are showing as below:

WBO:EVT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.45   Med: 11.83   Max: 19.99
Current: 2.45

During the past years, Evotec SE's highest Cyclically Adjusted PB Ratio was 19.99. The lowest was 2.45. And the median was 11.83.

WBO:EVT's Cyclically Adjusted PB Ratio is ranked worse than
61.14% of 651 companies
in the Drug Manufacturers industry
Industry Median: 1.76 vs WBO:EVT: 2.45

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Evotec SE's adjusted book value per share data for the three months ended in Dec. 2023 was €6.329. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.81 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Evotec SE Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Evotec SE's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Cyclically Adjusted PB Ratio Chart

Evotec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.16 15.40 16.86 4.64 5.64

Evotec SE Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.51 4.64 5.85 5.15 5.64

Competitive Comparison of Evotec SE's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Evotec SE's Cyclically Adjusted PB Ratio falls into.



Evotec SE Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Evotec SE's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=9.295/3.81
=2.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Evotec SE's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=6.329/123.6675*123.6675
=6.329

Current CPI (Dec. 2023) = 123.6675.

Evotec SE Quarterly Data

Book Value per Share CPI Adj_Book
201312 1.212 99.356 1.509
201403 1.189 99.543 1.477
201406 1.195 99.543 1.485
201409 1.184 99.823 1.467
201412 1.205 99.543 1.497
201503 1.242 99.717 1.540
201506 1.373 100.417 1.691
201509 1.343 100.417 1.654
201512 1.402 99.717 1.739
201603 1.369 100.017 1.693
201606 1.399 100.717 1.718
201609 1.456 101.017 1.782
201612 1.604 101.217 1.960
201703 2.351 101.417 2.867
201706 2.139 102.117 2.590
201709 2.167 102.717 2.609
201712 2.247 102.617 2.708
201803 2.297 102.917 2.760
201806 2.390 104.017 2.842
201809 2.643 104.718 3.121
201812 2.849 104.217 3.381
201903 3.006 104.217 3.567
201906 2.929 105.718 3.426
201909 3.065 106.018 3.575
201912 3.166 105.818 3.700
202003 3.236 105.718 3.785
202006 3.149 106.618 3.653
202009 3.112 105.818 3.637
202012 4.426 105.518 5.187
202103 4.819 107.518 5.543
202106 5.179 108.486 5.904
202109 6.012 109.435 6.794
202112 7.801 110.384 8.740
202203 7.402 113.968 8.032
202206 7.208 115.760 7.700
202209 6.943 118.818 7.226
202212 6.709 119.345 6.952
202306 6.627 123.140 6.655
202309 6.439 124.195 6.412
202312 6.329 123.668 6.329

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evotec SE  (WBO:EVT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Evotec SE Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Evotec SE's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE (WBO:EVT) Business Description

Industry
Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Evotec SE (WBO:EVT) Headlines